Register to get unlimited Level 2

Company Announcements

Director/PDMR Shareholding

Related Companies

By LSE RNS

RNS Number : 3055V
Clinigen Group plc
01 November 2017
 

1 November 2017

 

 

 

PDMR Share Dealing

 

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services group, announces that it was notified on 30 October 2017 that the following transaction took place on 30 October 2017.

 

Steve Glass, Chief Commercial Officer, sold 17,360 ordinary shares of 0.1 pence each in the Company at a price of 1131 pence per share.

 

Following this transaction, Mr Glass no longer holds any ordinary shares in the Company.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Steve Glass

2

Reason for the notification

a)

Position/status

Chief Commercial Officer / PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Sale of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

1131p

17,360

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

17,360

1131p

£196,342

f)

Date of the transaction

30 October 2017

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

 

 


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw / Deborah Bell

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

For more information, please visit www.clinigengroup.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFSELDLLIID

Top of Page